Attovia Therapeutics（ATTO）今日盘中大涨23.53%，引发市场广泛关注。
消息面上，该公司今日正式在纳斯达克上市交易。此前，Attovia Therapeutics将美国首次公开募股（IPO）规模扩大至2.89亿美元，以每股17美元的发行价售出1700万股，发行价处于原定15至17美元定价区间的上限。上市首日，该股开盘价即达到每股24美元，远高于发行价，显示出市场对其的高度热情。
Attovia Therapeutics总部位于加利福尼亚州圣卡洛斯，专注于研发免疫介导性疾病的治疗方案。其主要研发项目包括ATTO-1310，该药物正在开发用于治疗慢性瘙痒性疾病。此次IPO的联合簿记管理人包括摩根士丹利、Leerink Partners、花旗集团和加拿大皇家银行资本市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.